1. Swerdlow, SH, Campo, E, Pileri, SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375–2390.
Google Scholar | Crossref | Medline | ISI2. Nguyen, LN, Ha, CS, Hess, M, et al. The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum. Int J Radiat Oncol Biol Phys 2000; 47: 1281–1285.
Google Scholar | Crossref | Medline3. van Besien, K, Kelta, M, Bahaguna, P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol 2001; 19: 1855–1864.
Google Scholar | Crossref | Medline | ISI4. Bledsoe, JR, Redd, RA, Hasserjian, RP, et al. The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. Am J Hematol 2016; 91: E436–E441.
Google Scholar | Crossref | Medline5. Kim, H-J, Kim, HK, Park, G, et al. Comparative pathologic analysis of mediastinal B-cell lymphomas: selective expression of p63 but no GATA3 optimally differentiates primary mediastinal large B-cell lymphoma from classic Hodgkin lymphoma. Diagn Pathol 2019; 14: 133.
Google Scholar | Crossref | Medline6. Lazzarino, M, Orlandi, E, Paulli, M, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 1993; 11: 2306–2313.
Google Scholar | Crossref | Medline7. Rodig, SJ, Savage, KJ, Nguyen, V, et al. TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. Am J Surg Pathol 2005; 29: 196–203.
Google Scholar | Crossref | Medline | ISI8. Copie-Bergman, C, Plonquet, A, Alonso, MA, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol 2002; 15: 1172–1180.
Google Scholar | Crossref | Medline | ISI9. Dorfman, DM, Shahsafaei, A, Alonso, MA. Utility of CD200 immunostaining in the diagnosis of primary mediastinal large B cell lymphoma: comparison with MAL, CD23, and other markers. Mod Pathol 2012; 25: 1637–1643.
Google Scholar | Crossref | Medline10. Guiter, C, Dusanter-Fourt, I, Copie-Bergman, C, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood 2004; 104: 543–549.
Google Scholar | Crossref | Medline11. Rosenwald, A, Wright, G, Leroy, K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851–862.
Google Scholar | Crossref | Medline | ISI12. Savage, KJ, Monti, S, Kutok, JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871–3879.
Google Scholar | Crossref | Medline | ISI13. Twa, DD, Chan, FC, Ben-Neriah, S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 2014; 123: 2062–2065.
Google Scholar | Crossref | Medline | ISI14. Giulino-Roth, L, O’Donohue, T, Chen, Z, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol 2017; 179: 739–747.
Google Scholar | Crossref | Medline15. Hayden, A, Tonseth, P, Lee, DG, et al. Outcome of primary mediastinal large B-cell lymphoma using R-CHOP: impact of a PET adapted approach. Blood 2020; 136: 2803–2811.
Google Scholar | Crossref | Medline16. Martelli, M, Ceriani, L, Zucca, E, et al. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol 2014; 32: 1769–1775.
Google Scholar | Crossref | Medline17. Melani, C, Advani, R, Roschewski, M, et al. End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making. Haematologica 2018; 103: 1337–1344.
Google Scholar | Crossref | Medline18. Vassilakopoulos, TP, Michail, M, Papageorgiou, S, et al. Identification of very low-risk subgroups of patients with primary mediastinal large B-cell lymphoma treated with R-CHOP. Oncologist 2021; 26: 597–609.
Google Scholar | Crossref | Medline19. Henderson, TO, Amsterdam, A, Bhatia, S, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 2010; 152: 444–455; w144–w154.
Google Scholar | Crossref | Medline | ISI20. Yusuf, SW, Venkatesulu, BP, Mahadevan, LS, et al. Radiation-induced cardiovascular disease: a clinical perspective. Front Cardiovasc Med 2017; 4: 66.
Google Scholar | Crossref | Medline21. Pinnix, CC, Smith, GL, Milgrom, S, et al. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2015; 92: 175–182.
Google Scholar | Crossref | Medline | ISI22. Shah, NN, Szabo, A, Huntington, SF, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol 2018; 180: 534–544.
Google Scholar | Crossref | Medline23. Vassilakopoulos, TP, Pangalis, GA, Katsigiannis, A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist 2012; 17: 239–249.
Google Scholar | Crossref | Medline24. Dunleavy, K, Pittaluga, S, Maeda, LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013; 368: 1408–1416.
Google Scholar | Crossref | Medline | ISI25. Camus, V, Berriolo-Riedinger, A, Lequesne, J, et al. R-CHOP14 as a standard of care in primary mediastinal B cell lymphoma: a 10-years experience of LYSA centers. In: ASH annual meeting, San Diego, CA, 5 December 2020.
Google Scholar | Crossref26. Todeschini, G, Secchi, S, Morra, E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004; 90: 372–376.
Google Scholar | Crossref | Medline | ISI27. Zinzani, PL, Martelli, M, Bertini, M, et al. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002; 87: 1258–1264.
Google Scholar | Medline | ISI28. Vassilakopoulos, TP, Papageorgiou, SG, Angelopoulou, MK, et al. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. Ann Hematol 2021; 100: 2279–2292.
Google Scholar | Crossref | Medline29. Schmitz, N, Zeynalova, S, Nickelsen, M, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2016; 34: 3150–3156.
Google Scholar | Crossref | Medline30. Boehme, V, Schmitz, N, Zeynalova, S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009; 113: 3896–3902.
Google Scholar | Crossref | Medline | ISI31. Papageorgiou, SG, Diamantopoulos, P, Levidou, G, et al. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without rituximab. Hematol Oncol 2013; 31: 10–17.
Google Scholar | Crossref | Medline32. Soumerai, JD, Hellmann, MD, Feng, Y, et al. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma 2014; 55: 538–543.
Google Scholar | Crossref | Medline33. Hamlin, PA, Portlock, CS, Straus, DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. Br J Haematol 2005; 130: 691–699.
Google Scholar | Crossref | Medline34. Lazzarino, M, Orlandi, E, Paulli, M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 1997; 15: 1646–1653.
Google Scholar | Crossref | Medline35. Sehn, LH, Antin, JH, Shulman, LN, et al. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. Blood 1998; 91: 717–723.
Google Scholar | Crossref | Medline36. Moskowitz, CH, Nademanee, A, Masszi, T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385: 1853–1862.
Google Scholar | Crossref | Medline | ISI37. Pro, B, Advani, R, Brice, P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 2017; 130: 2709–2717.
Google Scholar | Crossref | Medline38. Steidl, C, Gascoyne, RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011; 118: 2659–2669.
Google Scholar | Crossref | Medline39. Zinzani, PL, Pellegrini, C, Chiappella, A, et al. Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. Blood 2017; 129: 2328–2330.
Google Scholar | Crossref | Medline40. Jacobsen, ED, Sharman, JP, Oki, Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 2015; 125: 1394–1402.
Google Scholar | Crossref | Medline | ISI41. Green, MR, Monti, S, Rodig, SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116: 3268–3277.
Google Scholar | Crossref | Medline | ISI42. Roemer, MG, Advani, RH, Ligon, AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 2016; 34: 2690–2697.
Google Scholar | Crossref | Medline43. Chapuy, B, Roemer, MG, Stewart, C, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 2016; 127: 869–881.
Google Scholar | Crossref | Medline44. Shi, M, Roemer, MG, Chapuy, B, et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol 2014; 38: 1715–1723.
Google Scholar | Crossref |